Skip to main content
Caplight Logo









RevivBio

RevivBio

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://revivbio.com/

Last Round

Grant

Sep 1, 2024

Total Funding Raised

$3.63M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

RevivBio is a biotechnology company that operates a bioengineering and data-driven molecular design platform to develop functional biologics for crop, human, and animal health.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Water Treatment

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

protein engineeringenzyme designmicrofluidicsbiotech platformgenerative AIPFAS remediationin silico designfunctional biologicsmolecular designhigh-throughput screeningsynthetic biologyprotein designbiotech R&Dsmall business innovation researchSBIR

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

RevivBio Comparables

Compare RevivBio with similar companies based on industry and business-model similarity.

RevivBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Arzeda
75%
Adaptyv Bio
74%
Basecamp Research
73%

RevivBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 1, 2024
AcceleratorApr 2, 2024
SeedJan 16, 2024
AcceleratorMay 5, 2023
DebtJul 5, 2022

Key People

Founding team and executive leadership

Fatemeh Mastouri

CEO And Founder

Founding Team

RevivBio Investors

Notable investors and investment history

RevivBio investors
InvestorRounds
gener8torSeed
BioGenerator VenturesDebt, Seed
The Elizabeth Elting Venture FundAccelerator
Intel IgniteAccelerator
Tet VenturesSeed
Endless Frontier LabsAccelerator
Alumni VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 13, 2026

    Monthly visitors increased 36% MoM, reaching 2.9K.

  • Jul 29, 2026

    Monthly visitors increased 155% MoM, reaching 1.7K.

RevivBio Filings

Explore SEC and related filing metadata, where available.

RevivBio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about RevivBio's valuation, stock price, and market status.

Is RevivBio a public or private company?

RevivBio is a private company.

What is the current stock price of RevivBio?

RevivBio is a private company, so its shares have no public market price. Caplight tracks RevivBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is RevivBio worth (valuation)?

Valuation information for RevivBio is not publicly available.

Can I buy RevivBio stock?

RevivBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was RevivBio's last funding round?

RevivBio's most recent funding round was Grant on September 1, 2024.

Who are the main investors in RevivBio?

Key investors in RevivBio include Intel Ignite, National Science Foundation.

Will RevivBio IPO soon?

No public IPO plans have been announced for RevivBio.

How can I track RevivBio secondary market activity?

Caplight tracks bids, offers, and trades in RevivBio's shares on secondary markets.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range12
Year Founded2021
Last FundingSep 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?